On March 16-17, 2013, ISKCON and the Chinese Medical Doctor Association successfully held the second national autoimmune cell technology seminar in Beijing.

As a new type of tumor treatment, immune cell therapy overcomes the limitations of commonly used clinical surgery, radiotherapy and chemotherapy, opens up a new idea for tumor treatment, and shows broad application prospects.

In order to promote the scientific and orderly development of cell therapy technology, the state has issued a series of policies and regulations in the past few years to standardize the clinical research and application behavior of cell therapy and rectify the work of cell therapy. The Chinese Medical Doctor Association continues to be the third-class medical technology review agency, responsible for the technical review of the national third-class medical technology clinical application capabilities. In order to promote the development of medical science and the advancement of medical technology, and standardize the management of autoimmune cell (T cell, NK cell) treatment technicians, the Chinese Medical Doctor Association held the "Class III Medical Technology Review and Interpretation Cum in Beijing on March 16-17, 2013 The second national advanced training class for autoimmune cell (T cell, NK cell) treatment technicians".

The meeting implemented the principle of close integration of policy interpretation and clinical treatment, invited domestic authoritative experts to interpret relevant medical technology policies, regulations, standards and specifications, and made a centralized report on the frontiers of autoimmune cell research and clinical applications of the latest technology applications.

The chief scientist of ISKCON and Professor Yong Liu from Stanford University attended the meeting and gave a lecture entitled "Anti-tumor targeted immunotherapy based on dendritic cells transfected by recombinant adeno-associated virus carrying lung cancer-related antigen genes" .

As the inventor of ACTL technology, Professor Liu Yong introduced the principle, technical process and clinical application of ACTL technology in combination with the latest progress in tumor cell immunotherapy at home and abroad. He pointed out that ACTL, as a promising biological treatment technology, has many advantages that traditional treatment methods do not have, and a large number of clinical cases have proven its effectiveness and safety.

More than 800 industry professionals from all over the country gathered to listen carefully to Professor Liu Yong's cutting-edge research report on immune cell therapy research, and actively asked questions and actively communicated with Professor Liu Yong.

ACTL tumor cell targeted therapy technology is a new generation of tumor biotherapy technology developed after tumor biological immune CIK cells, NK cells, etc. It can be combined with radiotherapy and chemotherapy, and it is also suitable for independent treatment of patients with radiotherapy and chemotherapy. It provides a new cancer treatment method for oncologists. With the in-depth development of clinical research and the accumulation of evidence-based medical data, it can be expected that ACTL tumor cell targeted therapy technology will become a beneficial weapon for oncologists to fight tumors, and it will also bring more optimistic treatment hopes for Chinese cancer patients.